Cytocast Screener™
-
Decision: - Which compounds should be eliminated early?
-
Stage: - Hit-to-lead
-
Output: - High-throughput safety triage with early side-effect risk signals
CYTOCAST DIGITAL TWIN Platform™
for Predictive Drug Safety
Predict risk. Understand mechanisms. Advance the best.
AI- and simulation-powered prediction of clinically relevant side effects - mechanistic, interpretable, and early in discovery.
Modeling drug-induced biological perturbation across the human proteome to predict clinically observed side effects.
Where Cytocast fits in drug development
One platform. Three products. A continuous safety layer from early elimination to IND-ready nomination. Cytocast informs critical safety decisions across the pipeline.
Cytocast Optimizer™
- Decision:
- Which candidate has the best safety profile?
- Stage:
- Lead optimization
- Output:
- Comparative, mechanistic safety ranking across candidates
Cytocast Nominator™
- Decision:
- Which candidate should advance toward IND?
- Stage:
- Preclinical / IND-enabling
- Output:
- Decision-grade safety profile with clinical and mechanistic insight
Mechanistic safety prediction with interpretable biology
Cytocast links compound structure to clinical side effects through a mechanistic chain - from predicted target interactions to complex and pathway perturbations.
Compound
Targets & Off-targets
Perturbed Complexes & Pathways
Clinical Side Effects
Unlike black-box models, predictions are traceable, interpretable, and actionable.
Complements in vitro and in vivo safety assays by predicting clinically relevant side effects before experimental validation.
Systems-level simulation
Whole-cell, multi-tissue modeling
Mechanistic interpretability
Off-targets, pathways, and effects linked
Clinically grounded outputs
Real-world side effects, not proxies
Output & Value
Safety-related attrition remains a key driver of costly late-stage failure. Cytocast shifts safety assessment upstream, enabling decisions when programs can still be stopped, redesigned, or deprioritized at materially lower cost.
By moving safety earlier in the pipeline, Cytocast helps teams:
- Eliminate unsafe compounds before synthesis or animal studies
- Reduce candidate failure in IND-enabling toxicology
- Shift safety assessment upstream by months to over a year
Earlier insight. Better outcomes.
Diagram placeholder
Clinically interpretable outputs designed to support real R&D decisions,
not just data generation.
Decision-Enabling Outputs
Risk-ranked side-effect profiles
Clinically grounded safety risks prioritized for candidate selection and portfolio decisions.
Mechanistic explanation of safety liabilities
Predicted target interactions linked to downstream biological effects across tissues.
System-level perturbation insights
Traceable propagation through pathways, complexes, and tissues to explain emerging risk.
Confidence-tiered predictions
Predicted side effects stratified into confidence tiers to prioritize the strongest signals.
Validation & Trust
Performance grounded in real clinical endpoints and mechanistic interpretability.
Diagram placeholder
- 1000+ clinically observed side effects
- ~0.70 median balanced accuracy
- 7,700+ proteins modeled across 29 tissues
- Outperforms established models in binding affinity and off-target prediction
See Cytocast in action
Explore how mechanistic safety insights are generated from compound to clinical outcome.
Explore DemoA valuable tool to speed up development of new drugs.
Early identification of side-effects is a showstopper in the discovery path.
Cytocast is quite unique in this field of medical research and development.